New T-Cell Treatment for CD4 Positive T-Cell Cancers
Official title: CD4 Redirected Chimeric Antigen Receptor T Cell Therapy for CD4 Positive T Cell Neoplasms
Funded at Indiana University Indianapolis · NIH-11162445 · Data updated 2026-11-12
This clinical trial is exploring a new type of T-cell treatment for people with certain CD4 positive T-cell cancers that have not responded to previous therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Indiana University Indianapolis NIH-funded |
| Lab location | 1 site (Indianapolis, United States) |
| Project start | September 20, 2020 |
| Project end | July 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $756,574 |
| NIH project number | 5R01FD006820-05 |
| Project ID | NIH-11162445 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are patients with CD4 positive T-cell lymphoma or leukemia that has returned or not responded to at least one prior standard therapy.
✕Less likely to help
Patients whose cancer is not CD4 positive or who have not received prior standard therapy may not benefit from this specific approach.
What this research studies
This is a first-in-human clinical trial to test a new approach called CD4 Redirected Chimeric Antigen Receptor T Cell Therapy, or CD4CAR. We will take a patient's own T-cells, modify them in the lab to specifically target and fight CD4 positive cancer cells, and then give them back to the patient. Before receiving these modified cells, patients will undergo a short course of chemotherapy to prepare their body. The main goal is to determine if this new treatment is safe and can be successfully manufactured for patients with relapsed or refractory CD4 positive T-cell lymphoma and leukemia.
Why it matters
Potential benefit: If successful, this new T-cell treatment could offer a new option for patients with CD4 positive T-cell cancers that have run out of other treatment choices.
How similar studies have gone: This is a "first-in-man" Phase I clinical trial, meaning this specific CD4CAR T-cell therapy is novel and has not been tested in humans before.
Where this research is happening
-
Indiana University Indianapolis
Indianapolis, United States Active
Researchers
- Principal investigator: Salman, Huda — Indiana University Indianapolis
- Study coordinator: Salman, Huda
Related research
Other NIH-funded projects on the same topics.
-
Biomarker clues to catch pancreatic cancer early in cysts
A study from UC San Diego is testing blood and cyst-fluid markers to help tell high-risk pancreatic cysts from low-risk ones so that people with pancreatic cysts can get the right care sooner.
-
Myeloproliferative Neoplasm Research Consortium
A large research collaboration across multiple centers aims to improve survival for patients with myelofibrosis and related myeloproliferative neoplasms through coordinated laboratory, translational, and clinical work.
-
Understanding how different CALR mutations drive certain blood cancers
This grant explores how two CALR mutation types cause myeloproliferative neoplasms and could lead to better treatments for people with these blood cancers.
-
Cell Competition in Myeloproliferative Neoplasms
This NIH grant explores how healthy and mutant blood stem cells interact in certain blood cancers to understand why some patients progress and how future therapies might help.
-
Targeting ERK’s brake pedals to slow cancer progression
Aims to block the parts of ERK signaling that speed up cancer progression, by guiding drugs to the substrate-binding domains that act like accelerator pedals in myeloproliferative neoplasms and related cancers.
-
Biomarker work to predict pancreatic IPMN cancer risk
A Duke University researcher is testing biomarkers to tell which pancreatic IPMN cysts are likely to become invasive cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.